Cowen Starts Allena Pharmaceuticals (ALNA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Wedbush Starts Allena Pharmaceuticals (ALNA) at Outperform; Sees $3B Blockbuster Sales Potential from ALLN-177
November 27, 2017 6:32 AM ESTWedbush initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Outperform rating and a price target of $30.00.
Analyst Liana Moussatos sees ALNA as an opportunity to invest in oral enzyme treatments for patients with severe metabolic and kidney disorders.
They project cash... More
Jefferies Starts Allena Pharmaceuticals (ALNA) at Buy
November 27, 2017 2:08 AM ESTJefferies initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Buy rating and a price target of $22.00.
Analyst Matt Andrews believes the company's drug, ALLN-177, will be "The Next Big Metabolic Enzyme Blockbuster."
For an analyst ratings summary and ratings history on... More
